V.N. OSLOPOV¹, YU.V. OSLOPOVA², E.V. KHAZOVA¹, E. R. GIRFANUTDINOVA¹

 ¹Kazan State Medical University, Kazan

²Kazan (Volga) Federal University, Kazan

 Contact details:

Khazova E.V. — PhD (medicine), Associate Professor of the Department of Internal Diseases Propedeutics named after Professor S.S. Zimnitsky

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-905-313-97-10, e-mail: hazova_elena@mail.ru

 The leading death cause in the world is diseases of the cardiovascular system, with CHD as the leader in the structure of cardiovascular diseases. The cause of this disease is atherosclerosis. One of the possible causes of atherosclerosis is an increase in LDL-C and a decrease in HDL-C in the blood. Many epidemiological studies have reliably shown that HDL cholesterol reduces the risk of developing cardiovascular diseases. Data from recent studies cast doubt on this data. The review briefly describes the current understanding of the effect of HDL-C high levels on morbidity and mortality, lists the new approaches to assessing the role and function of these particles, presents the results of clinical studies of drugs that affect their concentration in blood plasma and the probable causes leading to an increase of the HDL-Cin content in the blood.

Key words: HDL-C, atherosclerosis, dyslipidemia.

REFERENCES

1. Shorstova O.V., Leyfer E.V. Rol’ vasa vasorum v patogeneze ateroskleroza. Materialy IV Vserossiyskoy mezhdistsiplinarnoy konferentsii, posvyashchennoy svetloy pamyati pervogo rektora NovGU Vladimira Vasil’evicha Soroki [The role of vasa vasorum in the pathogenesis of atherosclerosis. Materials of the IV All-Russian interdisciplinary conference dedicated to the blessed memory of the first rector of NovSU Vladimir Vasilyevich Soroka], 2020. Pp. 82–86.
2. Yur’eva E.A., Sukhorukov V.S., Vozdvizhenskaya E.S., Novikova N.N. Atherosclerosis: hypotheses and theories. Rossiyskiy vestnik perinatologii i pediatrii, 2014, no. 3, pp. 6–16 (in Russ.).
3. Dzhanaeva E.F., Shemetova G.N., Shirshova S.A. Pathogenetic foundations and modern approaches to early diagnosis of atherosclerosis. Fundamental’nye issledovaniya, 2012, no. 4 (2), pp. 264–269 (in Russ.).
4. Ateroskleroz i dislipidemii. Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel’yu profilaktiki i lecheniya ateroskleroza. Rossiyskie rekomendatsii, VII peresmotr [Atherosclerosis and dyslipidemia. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision], 2020, no. 1 (38), pp. 7–42 (in Russ.).
5. ESC/EAS recommendations for the treatment of dyslipidemias: lipid modification to reduce cardiovascular risk. Rossiyskiy kardiologicheskiy zhurnal, 2020, no. 25 (5), pp. 121–193 (in Russ.).
6. Susekov A.V. Low-density lipoprotein cholesterol (LDL-C) and non-HDL remnant cholesterol: is castling necessary to assess cardiovascular risk? Meditsinskiy sovet, 2013, no. 9, pp. 50–55 (in Russ.).
7. Schwartz G.G., Olsson A.G., Abt M. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012, vol. 367, pp. 2089–2099.
8. Tardif J.C., Ballantyne C.M., Barter P. et al. Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J, 2014, vol. 35, pp. 3277–3286.
9. Christian M. Madsen, Anette Varbo, Børge G. Nordestgaard. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. European Heart Journal, 2017, vol. 38, pp. 2478–2486.
10. Dennis T.Ko., David A. Alter, Helen Gu et al. High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions. The CANHEART Study. Journal of the American College of Cardiology, 2016, vol. 68 (19), pp. 2073–2083.
11. Van der Steeg W.A., Holme I., Boekholdt S.M. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol, 2008, vol. 51 (6), pp. 634–642.
12. Holzer M., Trieb M., Konya V. et al. Aging affects high-density lipoprotein composition and function. Biochim. Biophys. Acta, 2013, vol. 1831 (9), pp. 1442–1448.
13. Chun-Yao Huang, Feng-Yen Lin, Chun-Ming Shih et al. Moderate to High Concentrations of High-Density Lipoprotein From Healthy Subjects Paradoxically Impair Human Endothelial Progenitor Cells and Related Angiogenesis by Activating Rho-Associated Kinase Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, vol. 32, pp. 2405–2417.
14. Torkhovskaya T.I., Kudinov V.A., Zakharova T.S., Ipatova O.M., Markin S.S. Phosphatidylcholine of high density lipoproteins of blood plasma as a regulator of reverse cholesterol transport. Bioorganicheskaya khimiya, 2018, vol. 44 (6), pp. 608–619 (in Russ.).
15. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis Russian recommendations. VI revision. Ateroskleroz i dislipidemii, 2017, no. 3, pp. 5–22 (in Russ.).